BioPorto (THOX.F) Stock Overview
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
THOX.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.29 |
| 52 Week High | DKK 0.43 |
| 52 Week Low | DKK 0.23 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 23.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| THOX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.3% |
| 1Y | 23.6% | 26.9% | 15.4% |
Return vs Industry: THOX.F matched the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: THOX.F underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| THOX.F volatility | |
|---|---|
| THOX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: THOX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine THOX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 27 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| THOX.F fundamental statistics | |
|---|---|
| Market cap | US$123.97m |
| Earnings (TTM) | -US$7.48m |
| Revenue (TTM) | US$5.06m |
Is THOX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THOX.F income statement (TTM) | |
|---|---|
| Revenue | DKK 33.83m |
| Cost of Revenue | DKK 9.55m |
| Gross Profit | DKK 24.28m |
| Other Expenses | DKK 74.29m |
| Earnings | -DKK 50.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 71.76% |
| Net Profit Margin | -147.84% |
| Debt/Equity Ratio | 0% |
How did THOX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/23 18:46 |
| End of Day Share Price | 2024/06/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioPorto A/S is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Jyoti Prakash | Edison Investment Research |
| Yi Chen | H.C. Wainwright & Co. |